Recent studies showing that TRPV1 is involved in the cross-talk between cancer and immune cells in the TME [69] and that targeting TRPV1 can effectively increase tumor immune infiltration by suppressing TGF-β signaling in pancreatic and breast cancer models [70] support this hypothesis. Here, TRPV1 is linked to neoplasm.